Jane Street
AXSM icon

Jane Street’s Axsome Therapeutics AXSM Stock Holding History

Jane Street’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.8M Buy
170,700
+88,200
+107% +$19.1M ﹤0.01% 1565
2026
Q1 		$13.9M Buy
82,500
+27,700
+51% +$4.78M ﹤0.01% 2140
2025
Q4 		$10M Buy
54,800
+1,500
+3% +$209K ﹤0.01% 2314
2025
Q3 		$6.47M Buy
53,300
+32,500
+156% +$3.66M ﹤0.01% 3031
2025
Q2 		$2.17M Sell
20,800
-63,100
-75% -$6.68M ﹤0.01% 4289
2025
Q1 		$9.79M Sell
83,900
-76,500
-48% -$8.72M ﹤0.01% 2012
2024
Q4 		$13.6M Buy
160,400
+52,100
+48% +$4.79M ﹤0.01% 1614
2024
Q3 		$9.73M Buy
108,300
+77,000
+246% +$6.72M ﹤0.01% 1936
2024
Q2 		$2.52M Sell
31,300
-225,900
-88% -$16.7M ﹤0.01% 4106
2024
Q1 		$20.5M Buy
257,200
+198,100
+335% +$16.6M ﹤0.01% 1165
2023
Q4 		$4.7M Sell
59,100
-10,400
-15% -$695K ﹤0.01% 2943
2023
Q3 		$4.86M Sell
69,500
-21,000
-23% -$1.57M ﹤0.01% 2652
2023
Q2 		$6.5M Sell
90,500
-13,000
-13% -$959K ﹤0.01% 2396
2023
Q1 		$6.38M Sell
103,500
-56,400
-35% -$3.71M ﹤0.01% 2120
2022
Q4 		$12.3M Buy
159,900
+1,300
+0.8% +$77.7K 0.01% 1416
2022
Q3 		$7.08M Sell
158,600
-98,400
-38% -$4.92M ﹤0.01% 2112
2022
Q2 		$9.84M Buy
257,000
+226,800
+751% +$7.17M ﹤0.01% 1760
2022
Q1 		$1.25M Sell
30,200
-20,900
-41% -$648K ﹤0.01% 5661
2021
Q4 		$1.93M Sell
51,100
-73,800
-59% -$2.72M ﹤0.01% 4569
2021
Q3 		$4.12M Sell
124,900
-153,600
-55% -$5.99M ﹤0.01% 3061
2021
Q2 		$18.8M Sell
278,500
-85,000
-23% -$5.1M 0.01% 1120
2021
Q1 		$20.6M Buy
363,500
+170,800
+89% +$12M 0.01% 945
2020
Q4 		$15.7M Sell
192,700
-153,300
-44% -$11.5M 0.01% 1049
2020
Q3 		$24.7M Buy
346,000
+3,000
+0.9% +$234K 0.01% 662
2020
Q2 		$28.2M Buy
343,000
+303,100
+760% +$23.3M 0.02% 578
2020
Q1 		$2.35M Buy
39,900
+18,600
+87% +$1.52M ﹤0.01% 1864
2019
Q4 		$2.2M Buy
+21,300
New +$860K ﹤0.01% 1837

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jane Street's AXSM Position: Q2 2026 in Review

Jane Street increased its Axsome Therapeutics (AXSM) stake by 9,807% in Q2 2026, buying an estimated $86.7M and bringing the position to 403,995 shares worth $98.9M. The position accounts for 0.01% of the portfolio, ranked #944.

Jane Street first reported a position in AXSM in Q1 2019 and has held it in 29 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Jane Street held 403,995 shares of Axsome Therapeutics worth $98.9M as of Q2 2026.
  • Jane Street bought 399,917 Axsome Therapeutics shares in Q2 2026, an estimated $86.7M.
  • Axsome Therapeutics made up 0.01% of Jane Street's portfolio in Q2 2026, its #944 holding.
  • Jane Street first reported a position in Axsome Therapeutics in Q1 2019 and has held it in 29 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.